Sign inJoin
Company / Finance

Aurora Cannabis Inc.

ACB · NASDAQ

Aurora is trying to leave the worst cannabis-stock habits behind: Q3 FY2026 medical cannabis revenue set a record, management is exiting weaker Canadian consumer lanes, and the balance sheet has cash. The catch is that IFRS losses, Bevo restructuring, internal-control weaknesses, and an open ATM keep the turnaround on probation.

FollowAdd to WatchlistAsk Question
NASDAQACBCoverage BootstrapCannabisMedical CannabisTurnaround
Latest ReportMay 13, 2026Aurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 of 1 reports match
Clear filters
Selected tags
ACBCannabisNasdaq
Clear tags
MatchAny tagAll tags
Latest Thesis

Aurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilution

Aurora is trying to leave the worst cannabis-stock habits behind: Q3 FY2026 medical cannabis revenue set a record, management is exiting weaker Canadian consumer lanes, and the balance sheet has cash. The catch is that IFRS losses, Bevo restructuring, internal-control weaknesses, and an open ATM keep the turnaround on probation.

May 13, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
Aurora Cannabis Inc.Cannabis (ACB): the medical-cannabis turnaround trying to outrunMay 13, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
Aurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionAurora is trying to leave the worst cannabis-stock habits behind: Q3 FY2026 medical cannabis revenue set a record, management is exiting weaker Canadian consumer lanes, and the balance sheet has cash. The catch is that IFRS losses, Bevo restructuring, internal-control weaknesses, and an open ATM keep the turnaround on probation.NASDAQMay 13, 2026Research reportReadSlides